Vascular & Endovascular

Findings suggest hospitals that receive more transfers may have poorer outcomes simply based on their patient population.

Patients with acute stroke who were transferred to a hospital participating in a stroke registry in Michigan had significantly higher rates of in-hospital mortality and in-hospital complications compared with those who were not transferred.

Between 2005 and 2014, the cost of alteplase increased 111 percent from $30.50 for 1 mg to $64.30 for 1 mg. During that same time period, reimbursement from the Centers for Medicare and Medicaid Services (CMS) only increased 8 percent.

People with untreated hypertension have a nine-fold higher risk of having an intracerebral hemorrhage regardless of race compared with those who are receiving treatment, according to a prospective, multicenter, case-control study.

During the past decade, the cost of alteplase increased 111 percent, although reimbursement to hospitals for the clot-busting medication increased only 8 percent, according to an analysis.

Researchers and others in the healthcare industry are gathering this week in Los Angeles for the annual American Heart Association/American Stroke Association International Stroke Conference.

Steven E. Nissen, MD, of the department of cardiovascular medicine at the Cleveland Clinic, has questioned the validity of the updated dietary guidelines.

Three leading cardiology societies released a consensus statement on Dec. 10 regarding criteria institutions and operators should follow for left atrial appendage occlusion.

The FDA approved the AngioJet ZelanteDVT thrombectomy catheter on Nov. 30 to treat patients with deep vein thrombosis. The catheter also received a CE Mark on the same day for approval in Europe.

After 30 days of follow-up, 92.7 percent of patients with atrial fibrillation at high-risk for stroke who were implanted with the Watchman device did not have any serious adverse events, according to an analysis of an international registry. In addition, 98.5 percent of patients had a successful implantation, which was defined as deployment and release of the device into the left atrial appendage.

Researchers discovered a molecule that may be a potential therapy for patients recovering from a stroke. The molecule, known as growth and differentiation factor 10 (GDF10), is activated early after stroke, according to researchers from the department of neurology at the University of California, Los Angeles.